Replimune Group investors have until Sept. 2 to join securities fraud class action lawsuit.

A securities fraud class action lawsuit was filed against Replimune Group, Inc. (NASDAQ: REPL) for alleged misrepresentations and omissions related to the company's business and financial performance. Investors who purchased or acquired Replimune securities between November 22, 2024, and July 21, 2025, may be eligible to join the lawsuit and seek potential compensation.

A securities fraud class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) for alleged misrepresentations and omissions related to the company's business and financial performance. The lawsuit, filed by the Schall Law Firm [1], Kessler Topaz Meltzer & Check, LLP [2], and Levi & Korsinsky, LLP [3], alleges that Replimune made false and misleading statements about the prospects of its IGNYTE trial for RP1 (vusolimogene oderparepvec) during the period from November 22, 2024, to July 21, 2025. Investors who purchased or acquired Replimune securities during this time may be eligible to join the lawsuit and seek potential compensation.

The lawsuit alleges that Replimune overstated the prospects of its IGNYTE trial, which was later deemed inadequate and poorly controlled by the FDA. These misrepresentations led to investors suffering damages when the market learned the truth. The class action lawsuits seek to recover losses on behalf of investors who were adversely affected by the alleged securities fraud.

Investors who believe they may be eligible to join the lawsuit are encouraged to contact the respective law firms before the lead plaintiff deadline of September 22, 2025. The Schall Law Firm [1] can be reached at 310-301-3335 or via email at bschall@schallfirm.com. Kessler Topaz Meltzer & Check, LLP [2] can be contacted at (484) 270-1453 or info@ktmc.com. Levi & Korsinsky, LLP [3] can be reached at (212) 363-7500 or via email at or by telephone at (212) 363-7500.

It is important to note that the class has not yet been certified, and until certification occurs, investors are not represented by an attorney. Investors can choose to take no action and remain an absent class member. The lead plaintiff process involves selecting a representative investor or small group of investors who have the largest financial interest and are typical of the proposed class. The lead plaintiff selects counsel to represent the lead plaintiff and the class, and these attorneys, if approved by the court, are lead or class counsel.

The law firms involved in the lawsuit have extensive experience in securities class action lawsuits and shareholder rights litigation. They have a track record of recovering billions of dollars for investors who have suffered from fraud and other corporate misconduct.

For more information about the lawsuit and the firms involved, please refer to the following sources:
- [1] https://www.morningstar.com/news/pr-newswire/20250901la63015/repl-investors-have-opportunity-to-lead-replimune-group-inc-securities-fraud-lawsuit-with-the-schall-law-firm
- [2] https://www.morningstar.com/news/globe-newswire/9520491/repl-class-action-lawsuit-reminder-kessler-topaz-meltzer-check-llp-reminds-replimune-group-inc-repl-investors-that-a-securities-fraud-class-action-lawsuit-has-been-filed
- [3] https://www.prnewswire.com/news-releases/levi--korsinsky-notifies-replimune-group-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline--repl-302541664.html